Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Resectable Lung Non-Small Cell Carcinoma Clinical Trial

Official title: Proton Beam Radiation Therapy in Patients With Resected N2 Non-Small Cell Lung Cancer

Status Not yet recruiting

Clinical Trial Summary

This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest. Proton therapy is a type of radiation treatment that kills cancer cells while avoiding surrounding healthy tissue. Proton beam therapy is sometimes used after cancer surgery to reduce the risk of cancer recurrence (coming back). Giving proton beam radiation therapy may work better than conventional radiation treatment after surgery in patients with non-small cell lung cancer.

Clinical Trial Description

PRIMARY OBJECTIVE:

I. To assess the safety of proton beam radiation therapy (PBRT) for resected N2 non-small cell lung cancer (NSCLC).

SECONDARY OBJECTIVES:

I. To measure the radiation dose to the circulating immune compartment and explore its association with clinical endpoints.

II. To assess the efficacy of PBRT for resected N2 NSCLC.

OUTLINE:

Patients undergo radiation treatment planning and then undergo proton beam radiation therapy on study. Patients also undergo collection of blood samples.

Patients are followed up for 24 months after first dose of radiotherapy. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Resectable Lung Non-Small Cell Carcinoma

• NCT number: NCT06008730
• Study type: Interventional
• Source: Emory University
• Contact: Bill Stokes, MD
• Phone: 404-778-3473
• Email: william.stokes@emoryhealthcare.org
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 1, 2024
• Completion date: December 31, 2027